Biologics

Adalimumab (Humira)

Etanercept (Enbrel)

Ustekinumab (Stelara)
Infliximab (Remicade)

Infliximab (Remsima)
Secukinumab (Cosentyx)
Approved Clinical Indication
Plaque Psoriasis
Humira is indicated for the treatment of adult patients with moderate to severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy and when other systemic
therapies are medically less appropriate.

Pediatric Plaque Psoriasis

Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents
from 4 years of age who have had an inadequate response to or are inappropriate candidates for
topical therapy and phototherapy.

Psoriatic Arthritis
Humira is indicated for reducing signs and symptoms of active arthritis in adult patients with
moderate to severe psoriatic arthritis when the response to previous DMARD therapy has been
inadequate.

Plaque Psoriasis
Treatment of adults with moderate to severe chronic plaque psoriasis who failed to respond to, or
who have contraindications to, or are intolerant to other systemic therapy including cyclosporine,
methotrexate or PUVA.

Pediatric Plaque Psoriasis

ENBREL is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents
from the age of 6 years who are inadequately controlled by, or are intolerant to other systemic
therapies or phototherapies.

Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms of active arthritis in adult patients with
psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not
respond adequately to methotrexate alone.

Plaque Psoriasis
STELARA® is indicated for the treatment of adult patients (18 years or older) with moderate to severe
plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to
other systemic therapies including cyclosporin, methotrexate or PUVA.

Pediatric Plaque Psoriasis

STELARA® is indicated for the treatment of pediatric patients (12 years and older) with moderate to
severe plaque psoriasis who are inadequately controlled by, or are intolerant to, other systemic
therapies or phototherapies.

Psoriatic Arthritis (PsA)

STELARA®, alone or in combination with methotrexate (MTX), is indicated for:
• the treatment of adult patients (18 years or older) with active psoriatic arthritis when the response
to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been
inadequate
• inhibiting the progression of structural damage
Plaque Psoriasis
REMICADE® is indicated for:
Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a
contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate
or PUVA

Psoriatic Arthritis
REMICADE®, in combination with methotrexate, is indicated for:
Treatment of active and progressive psoriatic arthritis in patients who have responded inadequately
to disease-modifying anti-rheumatoid drugs.

Same as REMICADE®
Plaque Psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who
are candidates for systemic therapy

Psoriatic arthritis
Cosentyx is indicated for the treatment of active psoriatic arthritis in adult patients when the
response to previous disease-modifying anti-rheumatic drug (DMARD)
Approved Age
Adults (≥ 18 years)

Pediatric Patients (≥ 4 years)

Adults (≥ 18 years)

Adults (≥ 18 years)

Pediatric Patients (≥ 6 years)

Adults (≥ 18 years)

Adults (≥ 18 years)

Pediatric Patients (≥ 12 years)

Adults (≥ 18 years)
Adults (≥ 18 years)

Adults (≥ 18 years)

Same as REMICADE®
Adults (≥ 18 years)

Adults (≥ 18 years)